ZDA
ADPT icon

Zweig-DiMenna Associates’s Adaptive Biotechnologies ADPT Stock Holding History

Zweig-DiMenna Associates’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-159,490
Closed -$6.52M – 165
2021
Q2 		$6.52M Buy
159,490
+23,720
+17% +$922K 0.39% 93
2021
Q1 		$5.47M Buy
135,770
+1,000
+0.7% +$54.1K 0.38% 92
2020
Q4 		$7.97M Buy
134,770
+7,500
+6% +$387K 0.5% 71
2020
Q3 		$6.19M Buy
+127,270
New +$5.35M 0.42% 79

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Zweig-DiMenna Associates's ADPT Position: Q3 2021 in Review

Zweig-DiMenna Associates sold out of Adaptive Biotechnologies (ADPT) in Q3 2021, closing a stake of 159,490 shares — an estimated $6.52M sold.

Zweig-DiMenna Associates first reported a position in ADPT in Q3 2020 and held it in 4 quarters. The position peaked at $7.97M in Q4 2020. 219 funds tracked by Wall St. Rank hold ADPT as of Q3 2021.

  • Zweig-DiMenna Associates reported no remaining Adaptive Biotechnologies position as of Q3 2021 after selling out during the quarter.
  • Zweig-DiMenna Associates sold 159,490 Adaptive Biotechnologies shares in Q3 2021, an estimated $6.52M.
  • Zweig-DiMenna Associates first reported a position in Adaptive Biotechnologies in Q3 2020 and held it in 4 quarters.
  • Zweig-DiMenna Associates's Adaptive Biotechnologies position peaked at $7.97M in Q4 2020.
  • 219 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q3 2021.

Based on Zweig-DiMenna Associates's 13F filing for Q3 2021, filed 25 Oct 2021.